Is Repros Therapeutics Inc. (NASDAQ:RPRX) Overbought?

If the published price targets set by AT&T Inc. analysts have any power to influence the stock's share price, the highest price target set for T is $48. The average is taken over a specific period of time, like 10 days, 20 minutes, 30 weeks, or any time period the trader chooses. Consensus earnings estimates are far from flawless, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. That gives us a street projected return of 7.13%. If the stock is up it will have a positively weighted alpha. A stock that maintains a relatively stable price has low volatility.

Support is likely to come between $0.52 a share to $0.37 a share level. Stocks with a beta lower than the market are considered to be less risky while those with a higher beta are more risky than the market. In that case, its shares would mark a 45.59% decline from the most recent price.

In terms of volatility, the average daily high/low percentage range stands at 44.75% for the week and 18.79% for the month. The average volume for Neothetics, Inc. The latest exchange of 2.85 Million shares is below its average trading activity of 291.76 Million shares.

Separately, S&P Equity Research upped their price objective on Repros Therapeutics from $1.22 to $1.50 in a research report on Monday, January 30th.

Maximum and minimum EPS estimate for the current quarter is projected at $-0.32 and $-0.32, respectively, according to 1 analysts.

News stories about Repros Therapeutics (NASDAQ:RPRX) have trended negative recently, AlphaOne Sentiment Analysis reports.

Relative strength index (RSI-14) for Repros Therapeutics Inc.

Day One testimony continues in Jessica Chambers murder trial
She has said she spoke to her daughter on the evening of December 6, 2014, and will likely testify about that night. He also said that Mr Tellis had repeatedly asked Chambers for sex, and she had told him no, according to Fox news., Inc. (NASDAQ:AMZN): Financial Health and Analyst Ratings
The company was maintained on Monday, August 28 by KeyBanc Capital Markets. (NASDAQ:AMZN) on Monday, October 24 with "Buy" rating. The average Wall Street analyst rating for, Strong Buy, according to the average of 33 analyst scores.

Highly Traded Stock: Freeport-McMoRan Inc. (FCX)
After $0.17 actual EPS reported by Freeport-McMoRan Inc for the previous quarter, Wall Street now forecasts 35.29% EPS growth. Analysts are also projecting an Average Revenue Estimate for Freeport-McMoRan $3.91 Million in the Current Quarter.

The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $25.23M. EPS ratio determined by looking at last 12 month figures is -0.63.

Repros reported that the clinical development expenses pertaining to Proellex® dropped for the quarter closed June 30, 2017, versus the prior year period, following decreased expenses related with the company's Phase 2b clinical studies for the treatment of endometriosis and uterine fibroids. Values of %D line that are above 80 indicate that the security is overbought; prices could well fall in the near future. The Stochastic Oscillator is a powerful technical tool that is somewhat surprisingly easy to understand. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment. The 50 day moving average went up by +103.5217% whereas the 200 day average was up by +24.1426%. A reading under 20 would indicate no trend, and a reading from 20-25 would suggest that there is no clear trend signal.

After a recent technical review, shares of Repros Therapeutics (RPRX) have a 200-day moving average of 0.78.

Repros Therapeutics Inc. (RPRX) showed volatility of 41.79% over the past week.

The company now has an insider ownership of 0.2 Percent and Institutional ownership of 20.1 Percent. If Repros Therapeutics Inc.

Repros Therapeutics Inc. (RPRX)'s RSI (Relative Strength Index) is 89.42. Short shares increased from 1,187,885 to 1,197,977 over that timeframe. The typical day in the last one month has seen about a 17.55% volatility.

Latest News